Unlock instant, AI-driven research and patent intelligence for your innovation.

Chimeric Antigen Receptor Recognizing Carcinoembryonic Antigen and Its Application

A chimeric antigen receptor, carcinoembryonic antigen technology, applied in the field of genetic engineering, can solve the stability of antigen chimeric receptors. There is no good solution, and there is no report showing the stability of chimeric antigen receptor cells in CEA solid tumors To achieve the effect of strengthening the ability to proliferate and kill tumors, the ability to remove tumor cells, and a wide range of options

Active Publication Date: 2020-02-18
CHONGQING PRECISION BIOTECH CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] At present, there is no good treatment plan for solid tumors expressing CEA, and there is no good solution for the stability of antigen chimeric receptor transfection on T cells, and there is no report showing that M5A-scFv binds antigen chimeric receptor The stability of chimeric antigen receptor cells and the effect on the efficacy of CEA solid tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chimeric Antigen Receptor Recognizing Carcinoembryonic Antigen and Its Application
  • Chimeric Antigen Receptor Recognizing Carcinoembryonic Antigen and Its Application
  • Chimeric Antigen Receptor Recognizing Carcinoembryonic Antigen and Its Application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] Example 1 Construction of chimeric antigen receptor virus containing scFv of M5A, hMN-14, C2-45 and BW431 / 26

[0067] In order to prove that the anti-CEA CAR we screened has more advantages than the currently used anti-CEA CAR and other anti-CEA scFV CARs, it is necessary to simultaneously construct scFV-CARs of different anti-CEA humanized monoclonal antibodies and name them CEA-CAR- 1. CEA-CAR-2, CEA-CAR-3 and CEA-CAR-4 are as follows:

[0068] 1. Synthesis of gene sequences of chimeric antigen receptors targeting carcinoembryonic antigens containing different scFVs

[0069] Synthesize different single-chain antibody ScFv containing leader peptide (also known as signal peptide) (abbreviated as LP), anti-human CEA antigen, IgG4 hinge region (abbreviated as IgG4), CD28 transmembrane region or CD8 transmembrane region (abbreviated as TM) , whose structure is as figure 1 shown.

[0070] 2 Construction of lentiviral vectors expressing chimeric antigen receptors

[0071...

Embodiment 2

[0093] Example 2 Determination of affinity between scFv and target antigen (CEA)

[0094] The aforementioned four scFVs were tagged with His tags and cloned into plasmid vectors and transfected into HEK293 cells. The transfected cells were cultured for 6 days and all supernatants were collected. The supernatants were filtered through a 0.22um filter membrane and then purified by nickel column affinity chromatography. ScFV-His in the serum, the purity of scFV-His reached 95% after purification, and the concentration of scFV-His was determined by Bradford; the affinity of different scFV and CEA was measured by ForteBio RED96 interaction analyzer (Pall, CA, U.S.) was checked, and the experimental steps were carried out according to the instructions. The anti-human IgG-Fc (AHC) biosensor was purchased from Pall FortéBio, 1512121 according to the instruction manual; the concentration of recombinant CEA-Fc was 15ug / ml, purchased from Sino Biological Inc. Incubated in biosensors, s...

Embodiment 3

[0095] Example 3 Detection of Chimeric Antigen Receptor Maintenance in T Cells

[0096] 1 Isolation of Human Peripheral Blood Mononuclear Cells

[0097] Collect about 60ml of peripheral blood with anticoagulant-added blood collection tubes, divide into 30ml of 50ml centrifuge tubes, add 7.5ml of hydroxyethyl starch to dilute; naturally settle at room temperature (18-25°C) for about 30min, collect the upper layer of plasma, and The collected upper plasma was centrifuged at 1400rpm / min for 15min; then the pellet was resuspended with normal saline, added to the lymphocyte separation medium at a volume ratio of 1:1, gradient centrifuged at 400g / min, and the speed of the centrifuge was set to 1 , centrifuged for 20min; after centrifugation, the centrifuge tube was divided from top to bottom: the first layer: plasma layer; the second layer: annular milky white lymphocyte layer; the third layer: transparent separation liquid layer; the fourth layer: red blood cell layer; Take the se...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of gene engineering, and particularly relates to a chimeric antigen receptor for identifying carcino-embryonic antigens and an application of the chimeric antigen receptor. A single-chain fragment variable (scFV) for identifying the carcino-embryonic antigens, a hinge region, a transmembrane region and an intracellular signal domain are sequentially connected to form the chimeric antigen receptor, and the amino acid sequence of the single-chain fragment variable (scFV) for identifying the carcino-embryonic antigens includes M5A-scFV amino acid sequence or amino acid sequence acquired by performing random mutation on M5A-scFV polypeptide. When the chimeric antigen receptor identifies the carcino-embryonic antigens, T lymphocytes can be more stably expressed, the positive rate of a chimeric antigen receptor of a target CEA (carcino-embryonic antigen) can be maintained in the culture process of patient cells, proliferation capacity and tumor killing capacity of CAR-T (chimeric antigen receptor T lymphocytes) can be improved, the chimeric antigen receptor does not have toxic and side effects on confrontation of original negative cells, can be used for targeted treatment of tumors and high in humanization degree, immunogenicity of the CAR can be effectively reduced, and continuity and safety of the CAR-T in human bodies are improved.

Description

technical field [0001] The invention belongs to the field of genetic engineering, relates to a chimeric antigen receptor for recognizing carcinoembryonic antigen and its application, and also relates to a lentiviral vector containing the chimeric antigen receptor for recognizing carcinoembryonic antigen (CEA) scFV and its application. Background technique [0002] The production technology of monoclonal antibodies has gone through three stages: heterologous polyclonal antibodies produced by classical immunization methods; mouse monoclonal antibodies produced by cell engineering and human monoclonal antibodies produced by genetic engineering. When mouse-derived monoclonal antibodies are used for disease treatment, when mouse antibodies are used directly for human treatment, the heterogeneity of mouse antibodies will cause human anti-mouse antibody reaction (HAMA), resulting in antibody half-life Short, is cleared quickly in the circulatory system, loses efficacy. Therefore, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00C12N15/62C12N15/867C12N5/10A61K35/17A61P35/00
CPCA61K35/17C07K14/7051C07K14/70517C07K14/70521C07K14/70578C07K16/3007C07K2317/622C07K2319/02C07K2319/03C07K2319/33C12N5/0636C12N15/86C12N2510/00C12N2740/15043C12N2800/107
Inventor 不公告发明人
Owner CHONGQING PRECISION BIOTECH CO LTD